With the enactment of major drug pricing reform—including the Inflation Reduction Act (IRA), which arguably made the most significant changes to U.S. prescription drug pricing regulations in history—the reporting of drug...more
In FY 2020, the Department of Justice opened 1,079 new civil health care fraud investigations and had 1,498 civil health care fraud matters pending at the end of the fiscal year. The number of investigations targeting the...more
2/2/2022
/ Biden Administration ,
Board of Directors ,
Continuing Legal Education ,
Department of Justice (DOJ) ,
Enforcement ,
Government Investigations ,
Health Care Providers ,
Healthcare Fraud ,
Internal Investigations ,
Noncompliance ,
Physicians ,
Webinars
From Pricing to Compliance to Coordinated Care, a Wide Range of Critical Areas Saw Regulatory Changes in 2020 That Will Impact the Health Care and Life Sciences Industries in 2021—and Beyond. Find Out How Your Organization...more
3/3/2021
/ Best Practices ,
Compliance ,
Continuing Legal Education ,
Coronavirus/COVID-19 ,
Department of Health and Human Services (HHS) ,
Department of Justice (DOJ) ,
Enforcement Actions ,
False Claims Act (FCA) ,
Health Care Providers ,
Health Plan Sponsors ,
Hospitals ,
Life Sciences ,
Pharmaceutical Industry ,
Physicians ,
Prescription Drugs ,
Price Transparency ,
Regulatory Requirements ,
Webinars